The US reimbursement landscape for prescription drugs has been shifting rapidly over the last few years. Some of the major US access trends that have accelerated include: Payers increasing volume control over prescribed therapies, tightening formularies, and utilization management As the site-of-care landscape is consolidating, provider groups are incentivized to shift away from volume to … Continued
Author: Ulrich Neumann
This blog discusses the challenges that drug developers face in getting patients access to cell and gene therapies as well as some potential solutions.
Innovative contracts are helpful in navigating an evolving pharma marketplace while providing new approaches to distributing life-saving treatments to patients.
“Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled” Bob Dylan recorded his iconic “The Times They Are a Changin’” in 1963; the song was released on the 1964 album by the same name. One of … Continued
We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported Price Increases.”
The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm on real-world evidence (RWE) and its adoption in the drug development process. While the collection of real-world data (RWD) and use of RWE is not new, they are now poised to have a profound impact on our industry. Today, it … Continued